CLDX · Celldex Therapeutics, Inc.
$31.79
+0.14 (+0.44%)
At close · Oct 5
Return incl. dividend (before tax)
Market Cap
$2.50B
Shares
78.53M
Volume · Oct 5
272.05K
Avg daily vol (3M)
1.26M
Price & Indicators
20d MA
50d MA
200d MA
Earnings
Filing
Insider
Congress
Investor day
Close$31.65
Open$32.26
Day$30.98–32.54
52W close$22.58–44.87
Avg vol 30d1.6M
Short int9.0M · 11.4% float · 13.1d
Short vol38%
Last earningsSep 22, 2026
DataJan 2020–Oct 2026
Filing10-Q · Aug 6
Up next
Next earnings call
Feb 9, 2028
Est · unconfirmed
· in 70 wks
filed Aug 6, 2026
call held Feb 28, 2022
Metrics snapshot
Useful current figures from the complete screener profile.
Revenue (TTM)
—
Trailing 12 months
Net income (TTM)
—
Trailing 12 months
Revenue growth YoY
—
Year over year
Operating margin
—
Trailing 12 months
P / E (TTM)
—
Trailing earnings
FCF yield
—
TTM · current market cap
Return on invested capital
—
Trailing 12 months
Net cash
—
Latest balance sheet
Dividend yield
—
Trailing 12 months
Shares change YoY
—
Year over year · more shares
Price change (1Y)
+22.4%
Trailing year
Short interest
11.4%
Latest settlement · 13.1 days to cover
Equibles Rating
blended score · not investment adviceOverall
Sell
SellHoldBuy
Technical
Sell
Momentum
Weak
Sentiment
Neutral
Fundamentals
Weak
Quant / Vol
Very High
Market backdrop
VIX 15.3 · calm
Equity put/call 0.58
Technical
price trend
50 / 200-day cross
No cross
Price vs 200-day avg
−2%
below
Price vs 50-day avg
−17%
below
RSI (14)
31
neutral
MACD trend
Negative
52-week position
41%
mid-range
Volume (OBV)
Confirms
volume backs price
Momentum
relative strength
1-month return
−20%
trailing
6-month return
−3%
trailing
YTD return
+17%
this year
Relative strength
−15%
vs S&P · 6-mo
Sentiment
smart money
Trend (MA cross)
No cross
50d $38 › 200d $32 — 50d above 200d
Institutional flow
Flat
1 of 258 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
11.40% of float · ▲ +3.6% MoM · 13.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
258 holders — near 3-yr high, broad support
Squeeze score
65
elevated · 0–100
Fundamentals
Revenue growth
+88%
Y/Y
EPS growth
−59%
Y/Y
Free cash flow
$-213.7M
Quant / Vol
risk profile
Volatility
52%
annualized · 1-yr
Max drawdown
−31%
past year
ATR
5.7%
of price · 14-day
Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.
Technicals
trend & momentum for long-term holders Sell
50 / 200-day cross
No cross
Neutral
Price vs 200-day avg
−2%
Neutral
Price vs 50-day avg
−17%
Bearish
RSI (14)
31
Neutral
MACD trend
Negative
Bearish
52-week position
41%
Neutral
Volume (OBV)
Confirms
Neutral
Market signals — smart money & positioning
Mixed
Trend (MA cross)
No cross
50d $38 › 200d $32 — 50d above 200d
Institutional flow
Flat
1 of 258 funds reported for Sep 30 · net 0 sh shares
Insider flow
Flat
No net insider activity over 90 days
Short interest
Rising
11.40% of float · ▲ +3.6% MoM · 13.1 days cover
Volume signal
Normal
Volume near normal
Institution breadth
Multi-yr high
258 holders — near 3-yr high, broad support
Price context
position in its 52-week range
Range low $23
Now $32 · 41%
Range high $45
vs 200-day avg -2%
vs 50-day avg -17%
Illustrative technical + ownership context — a signal mix, not investment advice.
Key metrics
the company's own KPIs, from written earnings releases and filings| Metric | Latest | Period | YoY |
|---|---|---|---|
| Patients enrolled in EMBARQ-CSU1 and EMBARQ-CSU2 | 1,939 | second quarter ended June 30, 2026 | — |
| Shares outstanding | 78.5M | second quarter ended June 30, 2026 | — |
Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period
Versus peers
Biotechnology — same industry group| Company | Mkt cap | YTD | Rev growth Y/Y | P/E | Short % shares |
|---|---|---|---|---|---|
|
CLDX
this stock
Celldex Therapeutics, Inc.
|
$2.50B | +16.5% | +87.8% | — | 11.4% |
|
VRTX
Vertex Pharmaceuticals Inc / Ma
|
$133.37B | +11.3% | +46.2% | 30.7 | 1.9% |
|
REGN
Regeneron Pharmaceuticals, Inc.
|
$81.13B | -4.8% | +20.8% | 19.5 | 2.5% |
|
MRNA
Moderna, Inc.
|
$79.40B | +544.3% | +4.3% | — | 8.2% |
|
CSLLY
Csl Ltd
|
$61.25B | — | — | — | 0.0% |
Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding
At a glance
key data from every sectionOwnership
Short & Settlement
Financials
Filings
Earnings & Events
Performance
| 5D | 20D | 120D | MTD | YTD | |
|---|---|---|---|---|---|
| CLDX | +1.8% | -19.6% | -2.9% | -2.3% | +16.5% |
| SPY | -0.2% | -0.5% | +12.2% | +0.9% | +12.9% |
| vs SPY | +2.0% | -19.2% | -15.1% | -3.3% | +3.7% |